Battered and bruised Dendreon Corp. has filed for Chapter 11 bankruptcy protection, assuring patients the Seattle company's prostate cancer treatment, Provenge (sipuleucel-T), will remain available as it advances plans to restructure its debt, either through a stand-alone recapitalization or company sale.